All In Biotech

Drug Trial Radar · NCT00547651

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 637 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

637

Actual

Start

Sep 1, 2007

Primary completion

May 1, 2011

Study completion May 1, 2011

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study drug (Amrubicin) is believed to work by stopping the tumor cells in your body from growing. The purpose of this study is to evaluate the effect of amrubicin compared to topotecan in the treatment of small cell lung cancer.

Conditions

  • Small Cell Lung Cancer

Interventions

  • AmrubicinDrug

    Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course

  • TopotecanDrug

    Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.Time frame: Until death from any cause

Locations

140 sites in 17 countries. Site status is shown where the registry gives one.

  • Northwest Alabama Cancer Center

    Muscle Shoals, Alabama

  • Arizona Oncology Associates

    Tucson, Arizona

  • Little Rock Hematology Oncology Associates

    Little Rock, Arkansas

  • Cancer Care Associates of Fresno Medical Group, Inc.

    Fresno, California

  • Cedars-Sinai Outpatient Cancer Center

    Los Angeles, California

  • University of Colorado Health Science Centre

    Aurora, Colorado

  • Rocky Mountain Cancer Center - Midtown (Main)

    Denver, Colorado

  • Advanced Medical Specialties

    Miami, Florida

  • Ocala Oncology Center

    Ocala, Florida

  • Cancer Centers of Florida, P.A.

    Ocoee, Florida

  • Florida Oncology Associates

    Orange Park, Florida

  • Sacred Heart Medical Oncology

    Pensacola, Florida

  • Medical Oncology Associates of Augusta

    Augusta, Georgia

  • Joliet Oncology-Hematology Associates, Ltd.

    Joliet, Illinois

  • Cancer & Hematology Specialists of Chicago (Main)

    Niles, Illinois

  • Illinois Cancer Care

    Peoria, Illinois

  • Cancer Care at Blessing Hospital

    Quincy, Illinois

  • Central Indiana Cancer Centers

    Indianapolis, Indiana

  • Hope Center

    Terre Haute, Indiana

  • Kansas City Cancer Center (Main)

    Overland Park, Kansas

  • Cancer Center of Kansas

    Wichita, Kansas

  • Jayne Gurtler MD, Laura Brizn MD, Angelo Russo MD, and Janet Burroff MD, APMC

    Metairie, Louisiana

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Maine Center for Cancer Medicine and Blood Disorders

    Scarborough, Maine

  • Sinai Hospital of Baltimore, Inc.

    Baltimore, Maryland

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Alliance Hematology Oncology, P.A. (Main)

    Westminster, Maryland

  • Kalamazoo Hematology and Oncology

    Kalamazoo, Michigan

  • Michigan Hematology & Oncology Institute

    Southgate, Michigan

  • University of Minnesota Medical Center, Cancer Center

    Minneapolis, Minnesota

  • Missouri Cancer Associates

    Columbia, Missouri

  • St. Joseph Oncology, Inc.

    Saint Joseph, Missouri

  • Comprehensive Care Centers of Nevada (Main)

    Las Vegas, Nevada

  • New York Oncology Hematology, P.C.

    Latham, New York

  • SUNY Upstate Medical University - Regional Oncology Center

    Syracuse, New York

  • Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Regional Cancer Care

    Durham, North Carolina

  • Cancer Centers of North Carolina (Main)

    Raleigh, North Carolina

  • Piedmont Hematology Oncology Associates

    Winston-Salem, North Carolina

  • Gabrail Cancer Center

    Canton, Ohio

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.